이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

단일군, 다기관 연구: ATTR-CM 환자를 위한 디지털 원격 모니터링 도구의 수용성과 실행 가능성 평가: ACO-Monitor (ACO-MONITOR)

2026년 10월 23일 업데이트: Bayer

트랜스티레틴 아밀로이드 심근병증(ATTR-CM) 환자에서 디지털 원격 모니터링 도구(Luscii)의 수용 가능성 및 실용성에 대해 더 알아보기 위한 관찰 연구

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

  • How quickly and how often participants and healthcare professionals use Luscii
  • How long Luscii is used by each person
  • How many times participants use Luscii after being reminded
  • How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

  • Support participants in using Luscii to share health information from home
  • Monitor how often and how easily Luscii is used
  • Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
  • Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

관찰

등록 (추정된)

60

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Heidelberg, 독일, 69120
        • Universitätsklinikum Heidelberg
      • Innsbruck, 오스트리아, 6020
        • Medizinische Universität Innsbruck
      • Pavia, 이탈리아, 27100
        • Policlinico San Matteo di Pavia

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records. Medical professionals who are directly involved in the participants' treatment and who have access to and will review the Luscii-captured data for routine care are asked to complete the study-specific questionnaires/forms.

설명

Inclusion Criteria:

For patients:

  • Adult (≥18 years at the date of signing the informed consent form (ICF)).
  • Diagnosis of either wild-type or variant ATTR-CM.
  • Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
  • Signed ICF.
  • Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.

For medical professionals:

  • Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care.
  • Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire.

Exclusion Criteria:

For patients:

  • Participation in an investigational program with interventions outside of routine clinical practice.
  • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.

For medical professionals:

  • Any current affiliation with Luscii, Bayer, or any of their affiliates.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Wild-type or variant ATTR-CM participants

Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Acceptance of Luscii among medical professionals
기간: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Acceptance of Luscii among participants with ATTR-CM
기간: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for medical professionals
기간: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for participants with ATTR-CM
기간: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of using the tool in real-world settings throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants
기간: At baseline (initial visit), at 6 months and at 12 months

Measured by the Patient Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
기간: At baseline (initial visit), at 6 months and at 12 months

Measured by the Healthcare Professional (HCP) Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
스크리닝 실패한 환자 수 (명)
기간: 기준 시점 (초기 방문)
기준 시점 (초기 방문)
스크리닝 실패 이유
기간: 기준 시점 (초기 방문 시)
기준 시점 (초기 방문 시)
Participant demographic characteristics: age
기간: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit)

At baseline (initial visit)
Participant demographic characteristics: sex
기간: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Participant demographic characteristics: race
기간: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Clinical characteristics: National Amyloidosis Centre (NAC) Stage
기간: At baseline (initial visit)

Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality

At baseline (initial visit)
Clinical characteristics: relevant comorbidities
기간: At baseline (initial visit)

ATTR-CM relevant comorbidities

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM prior medications
기간: At baseline (initial visit)

Concomitant medications administered within the past 12 months before initial visit

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM concomitant medications
기간: At baseline (initial visit)

Previously administered ATTR-CM related medications within the past 12 months before initial visit

At baseline (initial visit)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 30일

기본 완료 (추정된)

2028년 4월 15일

연구 완료 (추정된)

2028년 5월 15일

연구 등록 날짜

최초 제출

2026년 4월 23일

QC 기준을 충족하는 최초 제출

2026년 4월 23일

처음 게시됨 (실제)

2026년 4월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 26일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 23일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 23127

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .